Skip to main content

Advertisement

SpringerLink
Log in

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The tyrosine kinase inhibitor imatinib mesylate inhibits the function of the Bcr-Abl oncoprotein associated with Philadelphia-positive chronic myelogenous leukemia (CML). Anagrelide suppresses megakaryocyte proliferation and differentiation. The objectives of this study were to investigate the feasibility and safety of imatinib mesylate and anagrelide combination therapy in patients with Ph-positive CML or chronic myeloproliferative disorders (MPD) with persistent thrombocythemia.

Methods

This study was a retrospective review of all available records of patients with chronic MPD presenting to the M.D. Anderson Cancer Center between October 1998 and May 2002, treated with imatinib mesylate combined with anagrelide.

Results

Of 22 patients identified, 18 had Ph-positive CML (chronic phase, 16 patients; accelerated phase, 2 patients), 1 had agnogenic myeloid metaplasia (AMM), 2 had essential thrombocythemia (ET) and 1 had MPD transformed into refractory anemia with excess blasts (RAEB). The median age was 57 years (range 26–82 years). The median dose of imatinib mesylate administered was 400 mg (range 300–800 mg) and the median dose of anagrelide was 1.5 mg (range 0.5–4.0 mg). Imatinib mesylate and anagrelide combination therapy was feasible and tolerable. Of the 18 patients with Ph-positive CML, 15 in chronic phase and 1 in accelerated phase achieved a complete hematologic response (CHR), and 9 of the 18 achieved cytogenetic response (complete in 8 patients). No responses were noted in patients with AMM, ET or MPD transformed into RAEB.

Conclusions

The combination of imatinib mesylate and anagrelide was safe and was associated with an 89% CHR rate in patients with CML in chronic phase and persistent thrombocythemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Sawyers CL (1997) Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol 10:223

    CAS  PubMed  Google Scholar 

  2. Buchdunger E, Matter A, Druker BJ (2001) Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 1551:11

    Google Scholar 

  3. Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM (2001) Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program):87

  4. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E; International STICMLSG (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645

    CAS  PubMed  Google Scholar 

  5. Hughes T, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Capdeville R, Gathmann I, Bolton AE, Goldman GM, Radich J (2002) Molecular responses to imatinib (STI571) or interferon + ara-C as initial therapy for CML; results in the IRIS study. Blood 100:93a

    Google Scholar 

  6. Kantarjian HM, Talpaz M (2001) Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol 28:9

    Article  CAS  Google Scholar 

  7. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M (2002) Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100:1590

    CAS  PubMed  Google Scholar 

  8. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE (2002) Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 8:2177

    CAS  PubMed  Google Scholar 

  9. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M (2002) Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8:2167

    CAS  PubMed  Google Scholar 

  10. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M (2002) Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99:3547

    Article  CAS  PubMed  Google Scholar 

  11. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L, Bochinski K, Arlinghaus R, Talpaz M (2003) Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 101:97

    Article  CAS  PubMed  Google Scholar 

  12. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J (2003) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101:473

    Article  CAS  PubMed  Google Scholar 

  13. Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH (2002) Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 99:3854

    Article  CAS  PubMed  Google Scholar 

  14. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481

    Article  CAS  PubMed  Google Scholar 

  15. Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP (1988) Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 318:1292

    CAS  PubMed  Google Scholar 

  16. Tsimberidou AM, Giles FJ (2002) Essential thrombocythemia (ET): moving from palliation to cure. Hematology 7:315

    CAS  PubMed  Google Scholar 

  17. Tomer A (2002) Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 99:1602

    CAS  PubMed  Google Scholar 

  18. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome [comment]. N Engl J Med 344:1038 [erratum appears in N Engl J Med, 2001, 345:232]

    Google Scholar 

  19. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia [comment]. N Engl J Med 344:1031

    CAS  PubMed  Google Scholar 

  20. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530

    Article  CAS  PubMed  Google Scholar 

  21. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457

    Google Scholar 

  22. Cortes JE, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Rios MB, Thomas D, Ferrajoli F, Verstovsek S, Faderl S, Letvak L, Bochinski K, Kantarjian H (2002) High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML) in early chronic phase treated with imatinib at 400 mg or 800 mg daily. Blood 100:95a

    Article  Google Scholar 

  23. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost 23:379

    CAS  PubMed  Google Scholar 

  24. Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 92:69

    PubMed  Google Scholar 

  25. Pescatore SL, Lindley C (2000) Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother 1:537

    CAS  PubMed  Google Scholar 

  26. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928

    Article  CAS  PubMed  Google Scholar 

  27. Lyseng-Williamson K, Jarvis B (2001) Imatinib. Drugs 61:1765

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, University of Texas, M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas, 77030, USA

    Apostolia M. Tsimberidou, Dawn E. Colburn, Mary Alma Welch, Jorge E. Cortes, Srdan Verstovsek, Susan M. O'Brien, Maher Albitar, Hagop M. Kantarjian & Francis J. Giles

Authors
  1. Apostolia M. Tsimberidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dawn E. Colburn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary Alma Welch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jorge E. Cortes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Srdan Verstovsek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Susan M. O'Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maher Albitar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hagop M. Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Francis J. Giles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francis J. Giles.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsimberidou, A.M., Colburn, D.E., Welch, M.A. et al. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 52, 229–234 (2003). https://doi.org/10.1007/s00280-003-0651-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-003-0651-7

Keywords

Search

Navigation